Navigation Links
Misonix Adds Industry Veteran To Management Team

FARMINGDALE, N.Y., July 12, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has announced the addition of industry veteran, Christopher A. DeNicola, to its sales management team.  Mr. DeNicola joined the Company on July 1, 2012, as Senior Director of Sales – North America for its neurosurgery, spine surgery and orthopedic surgery products.  Products in this category are the SonaStar® Ultrasonic Surgical Aspiration System and the BoneScalpel™ Ultrasonic Bone Cutting System.

Mr. DeNicola, who is degreed in Management, has almost 20 years of successful sales management experience in Orthopedic Surgery, Neurosurgery and Podiatric Surgery, with a heavy concentration in Spine Surgery.  He has worked with direct, distributor and hybrid sales organizations.  Previous employers included EBI (a Biomet Company), Small Bone Innovations and Scient'x USA.  The Company expects that Mr. DeNicola's presence will add measurably to the rapid expansion of its Neuro/Orthopedic sales organization.

The SonaStar is used by neurosurgeons and general surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of safely making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.  Use of this product is being rapidly accepted by spine and skull-based surgeons on a worldwide basis.

"We are very pleased to add a sales executive of Chris DeNicola's experience and stature to our growing domestic sales organization," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.  "His knowledge of distributors, combined with his established relationships with physician thought leaders in our target markets, should prove to be quite valuable in rapidly expanding our domestic market presence."

About MisonixMisonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at

Safe Harbor StatementWith the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Investor Relations ContactsMisonix Contact:

Lytham Partners, LLCRichard Zaremba

Robert Blum, Joe Dorame, Joe Diaz631-694-9555

SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Exhibits at Major Worldwide Spine Conference
2. Misonix And SIAD Healthcare Renew Distribution Agreement For Italy
3. Misonix Announces New Distribution Agreement For Panama
4. CSS Health Technologies Hires Industry Leader as New Senior Vice President of Sales
5. ERT Acquires invivodata to Establish the Industrys Most Experienced Provider of Clinical Outcome Assessment Solutions
6. Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
7. Global Kidney Cancer Drugs Industry
8. Global Imaging Agents Industry
9. Global Veterinary Vaccines Industry
10. Global Clinical Diagnostics Automation Industry
11. Global Growth Factors (Blood And Tissue) Industry
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):